The prognostic value of CDK1 across cancers was analyzed using GEPIA2.0, and the results indicated that patients with various cancers, such as kidney renal clear cell carcinoma, brain lower grade glioma, liver hepatocellular carcinoma, and LUAD, with high CDK1 expression tended to have shorter OS (Figure 2F). This evidence concerns the gene CDK1 and cancer.